Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment

MLA

Vincenzo Carnovale, et al. “Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment.” Journal of Clinical Medicine, vol. 11, Nov. 2022, p. 6900. EBSCOhost, https://doi.org/10.3390/jcm11236900.

APA

Vincenzo Carnovale, Filippo Scialò, Monica Gelzo, Paola Iacotucci, Felice Amato, Federica Zarrilli, Assunta Celardo, Giuseppe Castaldo, & Gaetano Corso. (2022). Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment. Journal of Clinical Medicine, 11, 6900. https://doi.org/10.3390/jcm11236900

Chicago

Vincenzo Carnovale, Filippo Scialò, Monica Gelzo, Paola Iacotucci, Felice Amato, Federica Zarrilli, Assunta Celardo, Giuseppe Castaldo, and Gaetano Corso. 2022. “Cystic Fibrosis Patients with F508del/Minimal Function Genotype: Laboratory and Nutritional Evaluations after One Year of Elexacaftor/Tezacaftor/Ivacaftor Treatment.” Journal of Clinical Medicine 11 (November): 6900. doi:10.3390/jcm11236900.